Eran Broshy - 11 Nov 2025 Form 4/A - Amendment Insider Report for Theravance Biopharma, Inc. (TBPH)

Role
Director
Signature
/s/ Brett Grimaud, Attorney-in-Fact
Issuer symbol
TBPH
Transactions as of
11 Nov 2025
Net transactions value
-$667,150
Form type
4/A - Amendment
Filing time
14 Nov 2025, 06:00:16 UTC
Date Of Original Report
13 Nov 2025
Previous filing
22 May 2025
Next filing
01 Dec 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
BROSHY ERAN Director C/O THERAVANCE BIOPHARMA US, LLC, 901 GATEWAY BLVD, SOUTH SAN FRANCISCO /s/ Brett Grimaud, Attorney-in-Fact 14 Nov 2025 0001256230

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TBPH Ordinary Shares Sale $286,750 -15,500 -17% $18.50 75,704 11 Nov 2025 Direct F1
transaction TBPH Ordinary Shares Sale $263,500 -15,500 -20% $17.00 60,204 11 Nov 2025 Direct F1
transaction TBPH Ordinary Shares Sale $259,000 -14,000 -19% $18.50 60,204 11 Nov 2025 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TBPH Share Option (Right to Buy) Options Exercise $142,100 +14,000 +15% $10.15 107,878 11 Nov 2025 Ordinary Shares 14,000 $10.15 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transactions reported on this Form 4 were effected pursuant to the reporting person's Rule 10b5-1 trading plan adopted on March 14, 2024.
F2 The reporting person exercised stock options to acquire 14,000 Ordinary Shares and sold all such shares on the same day in a broker-assisted transaction. No shares were withheld for taxes. The transactions reported on this Form 4 were effected pursuant to the reporting person's Rule 10b5-1 trading plan adopted on March 14, 2024.
F3 This option was fully vested and exercisable (having vested as to 1/12th of the shares subject to the option upon completion of each continuous month of service following the original grant date and any remaining unvested shares vesting on the date of the next annual meeting of the company's shareholders provided continuous service through such date).

Remarks:

This Form 4/A is being filed to correct an administrative error in the number of Ordinary Shares reported as sold at $18.50 on November 11, 2025. The originally reported amount of 29,500 shares in Table I, Row 1 was incorrect; the correct amount is 15,500 shares. The number of Ordinary Shares beneficially owned following the transactions has been correspondingly adjusted in all three rows of Table I.